Glenmark Pharmaceuticals launches Akynzeo in India, Nepal

13 Jul 2018 Evaluate

Glenmark Pharmaceuticals has launched Akynzeo in India and Nepal under an exclusive licensing pact with Helsinn, Swiss pharma group. It is used to prevent chemotherapy-induced nausea and vomiting.

Helsinn has developed Akynzeo and Glenmark has exclusive marketing rights for it in India and Nepal.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2028.50 19.50 (0.97%)
14-Jan-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1709.45
Dr. Reddys Lab 1184.00
Cipla 1437.40
Zydus Lifesciences 886.00
Lupin 2179.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×